Stockscreener 앱 받기
2.67
8.10%
0.20
시간 외 거래:
2.68
0.01
+0.37%
전일 마감가:
$2.47
열려 있는:
$2.48
하루 거래량:
622.20K
Relative Volume:
1.38
시가총액:
$75.71M
수익:
-
순이익/손실:
$-28.85M
주가수익비율:
-1.9043
EPS:
-1.4021
순현금흐름:
$-25.62M
1주 성능:
+8.54%
1개월 성능:
+10.79%
6개월 성능:
+15.09%
1년 성능:
+45.90%
1일 변동 폭
$2.2801
$2.675
1주일 범위
$2.2801
$3.0288
52주 변동 폭
$1.11
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
명칭
Annovis Bio Inc
전화
484-875-3192
주소
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.67 | 70.04M | 0 | -28.85M | -25.62M | -1.4021 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-10-25 | 업그레이드 | Maxim Group | Hold → Buy |
| 2023-12-29 | 개시 | Canaccord Genuity | Buy |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
Annovis Bio Inc 주식(ANVS)의 최신 뉴스
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring - Investing.com
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - markets.businessinsider.com
Neurorpm To Deploy Ai-Enabled Digital Biomarker Monitoring For Annovis Bio's Parkinson's Disease Clinical Trial - TradingView
Wearables track Parkinson's symptoms in Annovis drug study - Stock Titan
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Shorts Report: Is Annovis Bio Inc stock forming a triangle pattern2026 Gainers & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Chart Watch: Should you avoid Annovis Bio Inc stock right now2026 Performance Recap & Low Risk High Win Rate Picks - baoquankhu1.vn
ANVS Technical Analysis & Stock Price Forecast - Intellectia AI
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients - MSN
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
Annovis Bio shares are trading higher. The company reported Q4 financial results.Annovis Bio (NYSE:ANVS) - Benzinga
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - Bitget
Annovis Bio, Inc. Announces Business Updates and Financial Results for Fiscal Year 2025, Highlighting Pivotal Advances in Buntanetap Development for Neurodegenerative Diseases - Quiver Quantitative
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) EstimateAnnovis Bio (NYSE:ANVS) - Benzinga
Annovis Bio (ANVS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Annovis Bio to present buntanetap clinical data at AD/PD 2026 conference - MSN
Annovis Bio (NYSE: ANVS) outlines late-stage Alzheimer’s and Parkinson’s program - Stock Titan
Annovis Bio’s Buntanetap: Advancing Clinical Development for Alzheimer’s and Parkinson’s Disease with Novel Multi-Targeted Approach 33 - Minichart
Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026 - TradingView
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Annovis Bio (ANVS) Short Interest & Short Float | Updated Mar 2026 $ANVS - MarketBeat
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Friday - MarketBeat
ANVS|Annovis Bio Inc|Price:2.490|Chg%:-0.09 - TradingKey
Published on: 2026-03-11 14:44:25 - baoquankhu1.vn
Annovis Bio to Present Buntanetap Clinical Data at AD/PD 2026 Conference - MyChesCo
Support Test: Is Annovis Bio Inc. stock technically oversold2026 WrapUp & Technical Confirmation Trade Alerts - baoquankhu1.vn
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards - MSN
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia - MSN
Momentum Shift: What makes Annovis Bio Inc stock attractive todayM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn
Annovis Bio Stock Price Drops 8.5%What's Next? - National Today
Annovis Bio (NYSE:ANVS) Stock Price Down 8.5%What's Next? - MarketBeat
Annovis CEO eyes spring breakthrough for Alzheimer’s drug - Longevity.Technology
Annovis Announces Two Presentations at the AD/PD 2026 International Conference - Bitget
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference - The Manila Times
AI Stocks: Will Annovis Bio Inc. benefit from rising consumer demandTrade Exit Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Annovis Bio Stock: Can Fresh Alzheimer’s Data Spark the Next Big Short Squeeze? - AD HOC NEWS
ANVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Annovis nears FDA threshold for Alzheimer's drug as CEO eyes spring milestone - The Business Journals
Tech Rally: Whats the analyst consensus on Annovis Bio Inc2025 Buyback Activity & AI Powered Market Entry Ideas - baoquankhu1.vn
Annovis Bio (ANVS): Alzheimer’s Data, Cash Burn and Why Traders Are Split - AD HOC NEWS
Should you avoid Annovis Bio Inc. stock right nowEarnings Recap Summary & Weekly Setup with ROI Potential - mfd.ru
Trading Action: Will Annovis Bio Inc. benefit from seasonalityJuly 2025 Weekly Recap & Technical Pattern Based Signals - mfd.ru
Is Annovis Bio Inc. a defensive stockJuly 2025 Final Week & Safe Capital Growth Trade Ideas - mfd.ru
Aug Analyst Calls: Will Annovis Bio Inc benefit from seasonalityQuarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Rate Hike: Can ADSE keep up with sector leadersJuly 2025 Setups & Verified Entry Point Detection - baoquankhu1.vn
Malvern-based Annovis continues phase 3 Alzheimer’s trial after safety review - MSN
Malvern-Based Annovis Continues Phase 3 Alzheimer’s Trial After Safety Review - MyChesCo
Will Annovis Bio Inc. stock rally after Fed decisionsJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - mfd.ru
Can Annovis Bio Inc. disrupt its industryJuly 2025 Institutional & Real-Time Volume Triggers - mfd.ru
Annovis Bio Inc (ANVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):